USPTO serial 87850414
PELEUS
Reviewed by CopyMark Law Group
Reg. 5743057Status 710
- Filing date
- Status date
- Registration date
- May 7, 2019
- Examiner
- PAINTER, VALERIYA SHERMAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with PELEUS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Stevenage
Stevenage
Stevenage, GB
ACHILLES THERAPEUTICS UK LIMITED
LONDON, GB
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Mark Harrison
MARK HARRISON VENABLE LLPP.O. BOX 34385WASHINGTON, DC 20043-9998UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations for therapeutic purposes namely, pharmaceutical and veterinary preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; pharmaceutical products for the diagnosis, prevention and treatment of cancer; pharmaceutical preparations for cancer therapy; antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; vaccines; pharmaceutical preparations for cell therapy; preparations for modifying human or animal cells for medical or therapeutic purposes; preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes | SECTION 8 - CANCELLED | — |
| 009 | Bioinformatics software for sequence data analysis; computer software platforms for sequence data analysis in the fields of cancer evolution and new cancer therapies, immune response disorders, genetic conditions, infectious diseases and vascular disease | SECTION 8 - CANCELLED | — |
| 040 | Custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies | SECTION 8 - CANCELLED | — |
| 042 | Scientific and technological services, namely, scientific research, design, analysis and testing in the field of cancer evolution and new cancer therapies; and research and design relating thereto; industrial analysis and research services in the field of new pharmaceutical products and new cancer therapies; medical and veterinary research services involving the manipulation of cells within a laboratory or research facility to enable the cells to be used for medical or therapeutic purposes; scientific research in the development of new cancer therapies; scientific research into cancer evolution and clonal architecture; scientific research in human and animal cell therapy; scientific research into vaccines; scientific research into preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services; providing software as a service for the identification of clonal neo-antigens; providing a bioinformatics platform as a service (PAAS) featuring computer software for sequence data analysis in the field of manufacturing therapeutics; providing a bioinformatics platform featuring computer software for identifying clonal neoantigens | SECTION 8 - CANCELLED | — |
| 044 | Medical services; veterinary services; medical services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients for therapeutic purposes; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Achilles Therapeutics Limited
- Other trademarks owned by Achilles Therapeutics Limited
- Other trademarks owned by Achilles Therapeutics Limited
- Other trademarks owned by ACHILLES THERAPEUTICS UK LIMITED
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PELEUS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| May 7, 2024 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Aug 4, 2021 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| May 7, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 19, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 19, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 30, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 1, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 28, 2018 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Dec 28, 2018 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Dec 28, 2018 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Dec 28, 2018 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 24, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 24, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 24, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 11, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 11, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 8, 2018 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 8, 2018 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 29, 2018 | NWAP | NEW APPLICATION ENTERED | — |